Article PDF
Avoid common mistakes on your manuscript.
References
Singla A, Lekhwani S, Vaswani ND, et al. Fourteen days vs 28 days of albendazole for neurocysticercosis in children: An open label randomized controlled trial. Indian Pediatr. 2022;59:916–9.
Garg D, Sharma S. Albendazole for neurocysticercosis in children: How long is long enough? Indian Pediatr. 2022; 59: 909–10.
Kongboonkiat K, Tiamkao S. Neurocysticercosis. Northeastern Thai Journal of Neurosciences. 2014;8:70–2.
Pokee N, Yasri R. Long term follow-up of pediatric cases with neurocysticercosis who received long-term albendazole therapy. Advances in Tropical Medicine Public Health International. 2022;3:3–4.
References
Singla A, Lekhwani S, Vaswani ND, et al. Fourteen days vs 28 days of albendazole for neurocysticercosis in children: An open label randomized controlled trial. Indian Pediatr. 2022;59:916–9.
Pokee N, Yasri R. Long term follow-up of pediatric cases with neurocysticercosis who received long-term albendazole therapy. Advances in Tropical Medicine Public Health International. 2022;3:3–4.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Kleebayoon, A., Wiwanitkit, V. & Kaushik, J.S. Prolonged Albendazole Therapy for Neurocysticercosis in Children. Indian Pediatr 60, 324 (2023). https://doi.org/10.1007/s13312-023-2870-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-023-2870-1